Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus | Zendy

Shufa Zheng | Zendy; Lingling Tang | Zendy; Hainv Gao | Zendy; Yiyin Wang | Zendy; Fei Yu | Zendy; Dawei Cui | Zendy; Guoliang Xie | Zendy; Xianzhi Yang | Zendy; Wei Zhang | Zendy; Xianfei Ye | Zendy; Zi-Ke Zhang | Zendy; Xi Wang | Zendy; Liang Yu | Zendy; Yiming Zhang | Zendy; Shigui Yang | Zendy; Weifeng Liang | Zendy; Yu Chen | Zendy; Lanjuan Li | Zendy

Open Access

Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus

Author(s) -

Shufa Zheng,

Lingling Tang,

Hainv Gao,

Yiyin Wang,

Fei Yu,

Dawei Cui,

Guoliang Xie,

Xianzhi Yang,

Wei Zhang,

Xianfei Ye,

Zi-Ke Zhang,

Xi Wang,

Liang Yu,

Yiming Zhang,

Shigui Yang,

Weifeng Liang,

Yu Chen,

Lanjuan Li

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix930

Subject(s) - medicine , neuraminidase , neuraminidase inhibitor , virology , influenza a virus subtype h5n1 , virus , influenza a virus , oseltamivir , zanamivir , orthomyxoviridae , covid-19 , disease , infectious disease (medical specialty)

The significance of early neuraminidase inhibitor (NAI) therapy for treating influenza A(H7N9) is currently unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore